Ann Thorac Surg 2007;83:138-139
© 2007 The Society of Thoracic Surgeons
Original Articles: Cardiovascular
Invited commentary
Hyun-Sung Lee, MD, PhD
Research Institute and Hospital, National Cancer Center, 809 Madu-1dong, Ilsandong-gu, Goyang, Gyeonggi, 411-769, Korea
(Email: thoracic@ncc.re.kr).
| The first 20% of the full text of this article appears below. |
Aspirin is widely used to reduce graft thrombosis after coronary artery bypass grafting. However, aspirin only prevents approximately 25% of all ischemic vascular events and there are many causes, including all the causes of aspirin resistance for the other events. Aspirin resistance is the inability of aspirin to block platelet production of thromboxane A2 and subsequent platelet activation and aggregation. Increasing degrees of aspirin resistance may correlate independently with increasing risk of . . . [Full Text of this Article]
Related Article
-
Dose-Related Efficacy of Aspirin After Coronary Surgery in Patients With PlA2 Polymorphism (NCT00262275)
- Eric Lim, Sebastian Carballo, Jacqueline Cornelissen, Ziad A. Ali, Robert Grignani, Sarah Bellm, and Stephen Large
Ann. Thorac. Surg. 2007 83: 134-138.
[Abstract]
[Full Text]
[PDF]
Copyright © 2007 by The Society of Thoracic Surgeons.